6855 — Ascentage Pharma International Income Statement
0.000.00%
Last trade - 00:00- HK$4.56bn
- HK$5.33bn
- CNY221.98m
Annual income statement for Ascentage Pharma International, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 14.5 | 12.4 | 27.9 | 210 | 222 |
| Cost of Revenue | |||||
| Gross Profit | 12.4 | 10.5 | 24.6 | 188 | 191 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 1,493 | 682 | 843 | 1,044 | 1,060 |
| Operating Profit | -1,478 | -669 | -816 | -834 | -838 |
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | -1,482 | -675 | -832 | -887 | -933 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -1,481 | -678 | -782 | -883 | -926 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | -1,481 | -678 | -782 | -883 | -926 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -1,481 | -678 | -782 | -883 | -926 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -12.5 | -3.14 | -3.07 | -3.35 | -3.28 |